BR112015020667A2 - método de preparar inibidores de glucosilceramida sintase - Google Patents

método de preparar inibidores de glucosilceramida sintase

Info

Publication number
BR112015020667A2
BR112015020667A2 BR112015020667A BR112015020667A BR112015020667A2 BR 112015020667 A2 BR112015020667 A2 BR 112015020667A2 BR 112015020667 A BR112015020667 A BR 112015020667A BR 112015020667 A BR112015020667 A BR 112015020667A BR 112015020667 A2 BR112015020667 A2 BR 112015020667A2
Authority
BR
Brazil
Prior art keywords
synthase inhibitors
glucosylceramide synthase
preparing
preparing glucosylceramide
treatment
Prior art date
Application number
BR112015020667A
Other languages
English (en)
Inventor
Siegel Craig
Zhao Jin
Reardon Michael
Gimi Rayomand
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of BR112015020667A2 publication Critical patent/BR112015020667A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D453/00Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Epidemiology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

resumo patente de invenção: “método de preparar inibidores de glucosilceramida sintase”. a invenção refere-se a um método de preparar inibidores de glucosilceramida sintase (gcs) úteis para o tratamento de doenças metabólicas, tais como doenças de armazenamento lisossomal, sozinhas ou em combinação com terapia de substituição de enzima, e para o tratamento de câncer.
BR112015020667A 2013-03-15 2014-03-13 método de preparar inibidores de glucosilceramida sintase BR112015020667A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361791913P 2013-03-15 2013-03-15
PCT/US2014/025384 WO2014151291A1 (en) 2013-03-15 2014-03-13 Method of preparing glucosylceramide synthase inhibitors

Publications (1)

Publication Number Publication Date
BR112015020667A2 true BR112015020667A2 (pt) 2017-07-18

Family

ID=50543333

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015020667A BR112015020667A2 (pt) 2013-03-15 2014-03-13 método de preparar inibidores de glucosilceramida sintase

Country Status (21)

Country Link
US (4) US9682975B2 (pt)
EP (2) EP2970251B1 (pt)
JP (2) JP6543242B2 (pt)
KR (1) KR20150130386A (pt)
CN (2) CN108658970A (pt)
AR (1) AR095436A1 (pt)
AU (2) AU2014235132B2 (pt)
BR (1) BR112015020667A2 (pt)
CA (2) CA3092901C (pt)
CY (1) CY1121859T1 (pt)
DK (1) DK3514157T3 (pt)
ES (2) ES2968073T3 (pt)
HK (1) HK1220689A1 (pt)
HU (2) HUE043394T2 (pt)
IL (2) IL240617B (pt)
MX (1) MX365464B (pt)
RU (1) RU2015144035A (pt)
SG (2) SG10201706575UA (pt)
TW (2) TW201900625A (pt)
UY (1) UY35438A (pt)
WO (1) WO2014151291A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20130273B1 (ar) 2012-09-11 2021-08-17 Genzyme Corp مثبطات انزيم (سينثاز) غلوكوسيل سيراميد
KR20150130386A (ko) 2013-03-15 2015-11-23 젠자임 코포레이션 글루코실세라마이드 신타아제 저해제의 제조 방법
EP3583653B1 (de) * 2017-02-17 2020-12-16 Westfälische Wilhelms-Universität Münster Elektrolyt-zusatz für lithium-ionen-batterien
JP2021506920A (ja) 2017-12-21 2021-02-22 リソソーマル・セラピューティクス・インコーポレイテッドLysosomal Therapeutics Inc. 結晶性の置換シクロヘキシルピラゾロ[1,5−a]ピリミジニルカルボキサミド化合物およびその治療的使用
US10519157B2 (en) * 2018-02-09 2019-12-31 X-Cutag Therapeutics, Inc. Deuterated compounds for treating Fabry, Gaucher, Parkinson's and related diseases and conditions, and compositions and methods thereof
IL295255A (en) 2020-02-03 2022-10-01 Genzyme Corp Methods for treating neurological symptoms associated with lysosomal storage diseases
WO2021221953A1 (en) 2020-04-28 2021-11-04 The Regents Of The University Of Michigan Pyridine inhibitors of glucosylceramide synthase and therapeutic methods using the same
CA3186766A1 (en) 2020-07-24 2022-01-27 Danielle Combessis Pharmaceutical compositions comprising venglustat

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB725226A (en) * 1952-06-03 1955-03-02 Berger Brothers Co Improvements in or relating to an inflatable surgical pad
GB725228A (en) * 1952-06-19 1955-03-02 Roche Products Ltd Substituted carbamic acid esters and process for the manufacture thereof
NL130759C (pt) * 1965-10-07
DE4326510A1 (de) * 1993-08-06 1995-02-09 Bayer Ag Verfahren zur Herstellung von Cyclohexen-Derivaten
KR970701174A (ko) * 1994-02-10 1997-03-17 오노다 마사요시 신규한 카바메이트 유도체 및 이의 의약 조성물(Novel carbamate derivative and medicinal composition containing the same)
JPH08198751A (ja) * 1995-01-19 1996-08-06 Yamanouchi Pharmaceut Co Ltd カルバメート誘導体
SE9600683D0 (sv) * 1996-02-23 1996-02-23 Astra Ab Azabicyclic esters of carbamic acids useful in therapy
GB0400812D0 (en) 2004-01-14 2004-02-18 Celltech R&D Ltd Novel compounds
US8003617B2 (en) 2004-11-10 2011-08-23 Genzyme Corporation Methods of treating diabetes mellitus
JP5285643B2 (ja) * 2010-03-15 2013-09-11 シャープ株式会社 半導体集積回路および電子情報機器
PL2639234T3 (pl) 2010-11-12 2019-12-31 Shionogi & Co., Ltd. Krystaliczna pochodna morfinanu 6,7-nienasyconego-7-karbamoilu i sposób jej wytwarzania
RU2645675C2 (ru) * 2011-03-18 2018-02-27 Джензим Корпорейшн Ингибиторы глюкозилцерамид-синтазы
EP2723734A1 (en) 2011-06-22 2014-04-30 Isochem Process for the preparation of solifenacin and salts thereof
JP2013053228A (ja) * 2011-09-02 2013-03-21 Asahi Kasei E-Materials Corp エポキシ樹脂用硬化剤及びマイクロカプセル型エポキシ樹脂用硬化剤
JOP20130273B1 (ar) 2012-09-11 2021-08-17 Genzyme Corp مثبطات انزيم (سينثاز) غلوكوسيل سيراميد
KR20150130386A (ko) * 2013-03-15 2015-11-23 젠자임 코포레이션 글루코실세라마이드 신타아제 저해제의 제조 방법

Also Published As

Publication number Publication date
HUE064200T2 (hu) 2024-02-28
IL240617B (en) 2019-08-29
CN105189491A (zh) 2015-12-23
ES2968073T3 (es) 2024-05-07
CN108658970A (zh) 2018-10-16
JP2019167379A (ja) 2019-10-03
US10065949B2 (en) 2018-09-04
AR095436A1 (es) 2015-10-14
CA3092901A1 (en) 2014-09-25
ES2727869T3 (es) 2019-10-21
EP2970251B1 (en) 2019-02-27
HK1220689A1 (zh) 2017-05-12
TW201900625A (zh) 2019-01-01
US20200181137A1 (en) 2020-06-11
SG11201506415XA (en) 2015-09-29
TW201524974A (zh) 2015-07-01
EP3514157A1 (en) 2019-07-24
MX365464B (es) 2019-06-04
US10954230B2 (en) 2021-03-23
JP2016512838A (ja) 2016-05-09
JP6543242B2 (ja) 2019-07-10
TWI649317B (zh) 2019-02-01
SG10201706575UA (en) 2017-09-28
RU2015144035A3 (pt) 2018-03-01
US20190031652A1 (en) 2019-01-31
AU2014235132B2 (en) 2018-08-02
CA2906581C (en) 2022-09-20
AU2014235132A1 (en) 2015-09-24
RU2015144035A (ru) 2017-04-20
DK3514157T3 (da) 2023-11-27
UY35438A (es) 2014-10-31
IL259770A (en) 2018-07-31
CY1121859T1 (el) 2020-07-31
CA3092901C (en) 2024-01-02
IL240617A0 (en) 2015-10-29
IL259770B (en) 2020-04-30
MX2015012842A (es) 2016-02-03
JP6813626B2 (ja) 2021-01-13
WO2014151291A1 (en) 2014-09-25
EP3514157B1 (en) 2023-09-06
KR20150130386A (ko) 2015-11-23
HUE043394T2 (hu) 2019-08-28
US10604518B2 (en) 2020-03-31
CA2906581A1 (en) 2014-09-25
AU2019200350A1 (en) 2019-02-07
US20160039806A1 (en) 2016-02-11
US20170334903A1 (en) 2017-11-23
US9682975B2 (en) 2017-06-20
CN105189491B (zh) 2018-07-06
EP2970251A1 (en) 2016-01-20

Similar Documents

Publication Publication Date Title
BR112013023774A2 (pt) inibidores de glicosilceramida sintase
TN2015000091A1 (en) Glucosylceramide synthase inhibitors
BR112015020667A2 (pt) método de preparar inibidores de glucosilceramida sintase
MX2016003486A (es) Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades.
MX2020009780A (es) Compuestos de inhibidor de autotaxina.
SG10201804952QA (en) Glucosylceramide synthase inhibitors
TN2015000427A1 (en) Salt forms of (S)-Quinuclidin-3-yl (2-(2-(4-fluorophenyl)thiazol-4-yl)propan-2-yl)carbamate
BR112018008931A8 (pt) ?compostos para tratamento de distúrbios hipoproliferativos?
WO2014165713A3 (en) Treatment of inflammatory conditions by modulation of hyaluronan and hyaluronidase activity
TN2013000368A1 (en) Glucosylceramide synthase inhibitors
PH12020500472A1 (en) Autotaxin inhibitor compounds

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: C07D 453/02 , C07D 417/06 , C07D 277/30

Ipc: C07D 453/02 (2006.01), C07D 417/06 (2006.01), C07D

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements